Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
Compliance with Ethical Standards
No sources of funding were received for the preparation of this response.
Conflict of interest
Amir Ansaripour, Carin A. Uyl-de Groot, and W. Ken Redekop have no conflicts of interest directly relevant to the content of this response.
- 2.Gershon N, Berchenko Y. Optimality, future costs and terminal costs. Pharmacoeconomics. 2018.Google Scholar
- 4.The World Bank. In: GDP per capita (current US$). 2015. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 20 Oct 2015.
© Springer International Publishing AG, part of Springer Nature 2018